Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
How VERVE-102 could accelerate the transition from chronic lipid therapy to genomic medicine
Could VERVE-102 shift cholesterol treatment from chronic therapy to one-time gene editing? Explore Eli Lilly and Company’s genomic medicine strategy.
Erasca (NASDAQ: ERAS) climbs into ASCO 2026 as pan-RAS thesis gets second wind
Erasca lost half its value on an IP challenge and a trial death. Now ASCO 2026 looms, Merck is on board, and traders are positioning before the verdict.
Can Fujifilm’s Madison iPSC facility turn stem cell science into scalable manufacturing?
iPSC demand is rising fast. Fujifilm’s Madison expansion tests whether stem cell manufacturing can keep pace with drug discovery and therapy scale-up.
Is Divi’s Laboratories still worth its premium after a steady Q4 profit beat?
Divi’s Laboratories posted Q4 profit growth and a ₹30 dividend, but margin pressure keeps valuation in focus. Read what #DIVISLAB signals now!
Can Bristol Myers Squibb turn Claude into pharma’s first enterprise AI operating layer?
Bristol Myers Squibb is moving Claude beyond chatbots. The bigger test is whether agentic AI can change how pharma actually works.
Aurobindo Pharma stock slips as USFDA OAI classification tests investor confidence in #AUROPHARMA
Aurobindo Pharma faces USFDA OAI pressure at a Telangana unit. Find out why this matters for #AUROPHARMA investors today!
Can Gujarat Themis Biosyn turn a Japanese acquisition into a global CDMO platform?
Gujarat Themis Biosyn is buying MicroBiopharm Japan for â‚ą1,300 crore. Find out why this CDMO bet matters for #GUJTHEM today!
Can CVC and Groupe Bruxelles Lambert’s Recordati bid reshape Italian pharma consolidation?
CVC and Groupe Bruxelles Lambert want Recordati private. Find out why the €10.7B bid could reshape Italian pharma consolidation.
Why clinicians and regulators are closely watching AstraZeneca’s rare disease and solid tumor pipeline strategy
Why AstraZeneca’s ASCO 2026 rare disease and solid tumor pipeline strategy is drawing major clinical and regulatory attention. Read more.
How confirmatory trial pressure could shape the future of HDV treatment markets
FDA approval gave Hepcludex a major HDV breakthrough, but confirmatory trials may decide its long-term future. Read the full analysis.